Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000, Australia
Signatory: Julian Babarczy, Chairman (Signed August 28, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a procedural submission to incorporate an exhibit by reference into existing registration statements (Forms S-8 and F-3) and does not contain a financial results table or narrative.
Material Changes
No material changes to financial performance or operations are disclosed in the text of this filing. The document focuses on regulatory compliance regarding the incorporation of Exhibit 99.1 (Appendix 4G) into prior registration statements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the cover page and signature block of the Form 6-K.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Appendix 4G), as the financial or operational details are likely contained within that attached document rather than the Form 6-K cover sheet.
- Confirm the status of the referenced Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Review the company's most recent Form 20-F for the latest audited financial data, as this filing does not include updated financial statements.